Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Epoetin Alfa as Adjuvant to Radiation in Head and Neck Cancer
NCT00017277Phase 3Terminated
- Sponsor
- European Organisation for Research and Treatment of Cancer
- Start
- Mar 2001
- Primary completion
- Apr 2003
- Modality
- Biologic, rProtein (Recombinant Protein)
- Countries
- 10
01
Overview
Phase 3, randomised, double-blind trial in head and neck squamous cell carcinoma (HNSCC) comparing RT + Epoetin alfa with RT + Placebo (2 arms). Primary endpoint: Local-regional control. Started Mar 2001; status: terminated.
02
Drugs
epoetin alfa
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT00017277.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00017277.